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FORMULASI DAN PENILAIAN PARTIKEL POLIMERIK BERMUATAN 
RIFAMPISIN UNTUK PENGHANTARAN PULMONARI 
 
ABSTRAK 
 
Partikel polimerik dibangunkan menggunakan polimer bioterdegradasikan 
PLGA dan mPEG-DSPE. Pengaruh berbagai parameter formulasi ke atas ciri-
ciri fisikal partikel polimerik dinilai. Parameter formulasi yang dinilai untuk PLGA 
ialah jenis polimer (RG 502, RG 503H dan RG 504), kepekatan PVA (2.5 dan 5 
% w/v) dan perkadaran drug dengan polimer (0.2:1, 0.5:1 and 1:1).  Parameter 
formulasi yang dinilai untuk mPEG-DSPE ialah jenis polimer (mPEG2000-DSPE 
dan mPEG5000-DSPE), perkadaran drug dengan polimer (1:5, 1:10 and 1.5:10) 
dan keliangan turas (0.22 dan 0.45 µm). Formulasi disediakan menggunakan 
kaedah pemeruapan pelarut dan amaun rifampicin terperangkap di dalam 
partikel polimer ditentukan menggunakan UV spektrofotometer. Purata saiz 
partikel mPEG-DSPE (241.5 nm) lebih kecil berbanding saiz partikel PLGA (3.7 
µm). Hasil mikropartikel PLGA (90.71 %) tidak dijejas oleh semua factor. Di 
antara PLGA yang diselidiki, PLGA 503H mempunyai  kecekapan 
pemerangkapan tertinggi iaitu 79.59 % pada kepekatan 5 % dan perkadaran 
drug dengan polimer 0.2:1.  Kecekapan pemerangkapan tertinggi mPEG-DSPE 
ialah 100% pada perkadaran drug dengan polimer 1:5 dan keliangan turas 0.45 
µm.  Jenis polimer dan keliangan turas tidak ada kesan ke atas kecekapan 
pemerangkapan, hasil dan muatan drug. Walaubagaimanapun, perkadaran 
drug dengan polimer berkadar negatif dengan kecekapan pemerangkapan 
nanopartikel. Analisis termal menggunakan DSC memperlihatkan Tg 
nanopartikal tersesar ke nilai rendah. Walaubagaimanapun, spectra FTIR tidak 
memperlihatkan cirri-ciri puncak drug dan polimer tersesar dan ini bermakna 
tiada interaksi kimia antara drug dan polimer dalam polimerik partikel.    
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 Pelepasan drug dari PLGA mikropartikel sangat perlahan berbanding mPEG-
DSPE nanopartikel. Pelepasan berkadar negative dengan jenis PLGA dan 
berkadar positif dengan perkadaran drug dengan polimer.  Kesan cetusan 
pelepasan diperlihatkan semasa pekadaran drug dengan polimer mencapai 1:1. 
Di antara PLGA-PLGA, pelepasan drug dari PLGA 503H mikropartikel berlaku 
paling cepat (14.11 % dalam masa 12 jam). Pelepasan dari PLGA sesuai 
dengan kinetik tertib sifar manakala PLGA 502 dan 503H masing-masing 
mengikut kinetik bieksponential. Sebaliknya, pelepasan dari mPEG-DSPE 
nanopartikles mengikut kenetik tertib pertama dan pelepasan drug paling cepat 
(58%) berlaku dalam masa 12 jam. Jenis mPEG-DSPE yang digunakan tiada 
kesan ke atas profile pelepasan drug dari nanopartikel.  Walaubagaimanapun, 
peningkatan perkadaran drug dengan polimer dan penignkatan keliangan turas 
akan memanjangkan masa pembebasan drug dari nanopartikel.  
 
MMAD mPEG-DSPE yang dihasilkan oleh nebulizer (2.6 µm) dan Rotahaler® 
(5.8 µm) yang dicirikan menggunakan NGI adalah lebih kecil dari pada aerosol 
MMAD PLGA 503H yang dihasilkan oleh nebulizer (6.9 µm) dan Rotahaler® 
(10.6 µm). Sebagai tambahan, FPF mPEG-DSPE (≈ 40 %) lebih tinggi dari 
pada FPF PLGA 503H (≈15 %). Seterusnya, kaedah perkadaran agar 1% 
digunakan untuk menguji keterentanan rifampisin terhadap mikobaterium. MIC 
mPEG-DSPE untuk strain sensitif drug (H37Rv) (10 µg/ml) dan strain rintang 
drug (JB74) (25 µg/ml) adalah rendah dari pada rifampisin mentah (masing-
masing 35 dan 200 µg/ml). Oleh itu, boleh diambil kesimpulan bahwa mPEG-
DSPE nanopartikel adalah pembawa yang sesuai untuk penghantaran 
rifampisin ke pulmonary.  
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FORMULATION AND EVALUATION OF RIFAMPICIN-LOADED POLYMERIC 
PARTICLES FOR PULMONARY DELIVERY 
 
ABSTRACT 
 
Polymeric particles were developed using PLGA and mPEG-DSPE 
biodegradable polymers. The influence of various formulation parameters on 
physical characteristics of polymeric particles was investigated. The formulation 
parameters investigated for PLGA were polymer type (RG 502, RG 503H and 
RG 504), PVA concentration (2.5 and 5 % w/v) and drug to polymer ratio (0.2:1, 
0.5:1 and 1:1).  The formulation parameters investigated for mPEG-DSPE were 
polymer type (mPEG2000-DSPE and mPEG5000-DSPE), drug to polymer ratio 
(1:5, 1:10 and 1.5:10) and filter porosity (0.22 and 0.45 µm). The formulations 
were prepared using a solvent evaporation method and the amount of rifampicin 
encapsulated in polymeric particles was quantified using a UV 
spectrophotometry. The mean particle size of mPEG-DSPE (241.5 nm) was 
smaller than PLGA (3.7 µm). The PLGA microparticles yield (90.71 %) was not 
affected by all factors. Among the PLGA studied, PLGA 503H had the highest 
entrapment efficiency with 79.59 % at a PVA concentration of 5 %w/v and drug 
polymer ratio of 0.2:1. The highest entrapment efficiency of mPEG-DSPE 
nanoparticles was 100 % at a drug to polymer ratio of 1:5 and filter porosity 0.45 
µm.  Polymer type and filter porosity had no effect on entrapment efficiency, 
yield and drug loading. However, drug to polymer ratio was negatively 
correlated with the entrapment efficiency of nanoparticles. Thermal analysis 
using DSC showed the Tg of nanoparticles shifted to a lower value. However, 
the FTIR spectra showed no shift in the characteristic peaks of drug and 
polymer which indicated no chemical interaction between drug and polymer in 
polymeric particles. 
 xxiv
 
Drug release from PLGA microparticles was much slower than mPEG-DSPE 
nanoparticles. The release was negatively correlated with PLGA type and 
positively correlated with drug to polymer ratio.  The burst effect was seen when 
drug to polymer ratio reached 1:1. Drug release from PLGA 503H microparticles 
was the fastest (14.11 % in 12 hours) among PLGAs. The release from PLGA 
504 fitted zero order kinetics whereas PLGA 502 and 503H followed 
biexponential first order kinetics.  Conversely, the release from mPEG-DSPE 
followed the first order release kinetics and the fastest drug released form 
nanoparticles (58%) occurred in 12 hours.  The mPEG-DSPE type used had no 
effect on the drug release profile from nanoparticles. However, increasing drug 
to polymer ratio and filter porosity would prolong the release of drug from 
nanoparticles.  
 
The MMAD of mPEG-DSPE generated by nebulizer (2.6 µm) and Rotahaler® 
(5.8 µm) characterized by NGI was smaller than the MMAD of PLGA 503H 
aerosols produced by nebulizer (6.9 µm) and Rotahaler® (10.6 µm). In addition, 
the FPF of mPEG-DSPE (≈ 40 %) was higher than the FPF of PLGA 503H (≈15 
%). Furthermore, 1% agar proportional method was used to test the 
susceptibility of rifampicin against mycobacteriums. The MIC values of mPEG-
DSPE for drug sensitive strain (H37Rv) (10 µg/ml) and drug resistant strain 
(JB74) (25 µg/ml) were lower than raw rifampicin (35 and 200 µg/ml 
respectively). Therefore, it can be concluded that the mPEG-DSPE polymer is a 
suitable carrier for pulmonary delivery of rifampicin. 
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CHAPTER 1  
GENERAL INTRODUCTION  
 
1.1 Tuberculosis  
Tuberculosis (TB) is a chronic communicable disease caused by the bacterium 
(Mycobacterium tuberculosis) and usually occurs in the lungs (the initial site of 
infection), but it also can occur in other organs. The complex nature of this 
pathogen and its ability to evade the immune system has prevented the 
development of an effective vaccine. TB is a highly contagious, persistent 
disease characterized by the formation of hard greyish nodules, or tubercles 
(Pandey et al., 2003).  
 
The World Health Organization (WHO) on 23 April 1993 declared tuberculosis 
as global public health emergency (Brennan, 1997; Makino et al, 2004). The 
disease infects over 1.8 billion people worldwide and it is responsible for 1.5 
million deaths annually (Pandey et al., 2003). Frieden et al. (2003) also affirmed 
Mycobacterium tuberculosis as being a leading cause of infectious mortality 
after HIV AIDS worldwide. Frieden et al. (2003) noted that there were an 
estimated of 8–9 million new cases of tuberculosis in 2000, 3–4 million cases 
were sputum-smear positive. Most cases (5–6 million) were in people aged 15–
49 years. Duncan and Barry (2004) said that according to a recent report 
compiled by the World Health Organization (WHO), the total number of new 
cases of tuberculosis (TB) worldwide in 2002 had risen to approximately 9 
million. This is despite the success of widespread of the ‘DOTS’ (directly 
observed therapy, short-course) strategy, now covering 180 countries and 
accessible by over 70% of the world's population. 
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Despite the availability of effective therapeutic regimens for the treatment of TB, 
treatment failure and emergence of drug resistant are still problematic. This 
treatment failure is related in part to patient non-compliance (due to frequent 
administration of anti-TB drugs). Patient-compliance can be improved by the 
use of sustained release antitubercular drugs formulations, which reduce the 
dosing frequency of the drugs. Such system can be designed to target specific 
regions of the lung, and therefore allow controlled drug delivery to lung, or to the 
systemic circulation via the lung (Fu et al., 2002; Prabakaran et al., 2004). 
 
1.2 Drug Therapy in Pulmonary Tuberculosis 
The goals of drug therapy are to ensure cure without relapse, to prevent death, 
to stop transmission and to prevent the emergence of multi-drug resistance 
tuberculosis (Frieden et al, 2003). Directly Observed Treatment, Short-course 
(DOTS) therapy, which lasts for 6 or 8 months, given under direct observation, 
is one of the most important components of WHO strategy against tuberculosis.  
 
Tuberculosis is treated in two phases. The initial phase for 2 months involves 
concurrent use of at least 3 drugs to reduce the bacterial population rapidly and 
prevent drug resistant bacteria emerging.  The second continuation phase for 4-
6 months involves fewer drugs and is used to eliminate any remaining bacteria 
and prevent recurrence. Direct observation of therapy is considered essential to 
ensure compliance during treatment of tuberculosis. Five drugs are considered 
essential first line for treatment of tuberculosis (Academy of Medicine of 
Malaysia 2nd edition. 2002). These are isoniazid (H), rifampicin (R), 
pyrazinamide (Z), streptomycin (S) (which are bactericidal) and ethambutol (E) 
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(which is bacteriostatic) are used in various combinations as part of WHO 
recommended treatment regimens. Isoniazid, rifampicin and pyrazinamide are 
components of all antituberculosis drug regimens currently recommended by 
WHO.  In supervised regimens change of drug regimen should be considered 
only if the patients fail to respond after 5 months of DOTS.  
 
Patients who cannot comply reliably with the treatment regimen drug 
administration needs to be fully supervised (directly observed therapy, DOTS) 
The patients are given daily doses of SHRZ or EHRZ or HRZ under supervision 
i.e directly observed by health personnel or trained person for the first 2 months 
followed by HR or SHR or HR, 2 –3 times a week for a further of 4 months 
(Academy of Medicine of Malaysia 2nd edition. 2002). Frieden et al., (2003) 
reported that the DOTS method could ensure high rates of treatment 
completion, reduce development of acquired drug resistance, and prevent 
relapse.  
 
Second line drugs in TB therapy are reserved for use only if the bacteria are 
resistant to the first line agents or if the patient experiences toxic side effects to 
them. The 2nd line drugs are much less active and have a much higher toxicity. 
Examples of second line drugs are ofloxacin/Ciprofloxacin, ethionamide, 
aminosalicylate, cycloserine, amikacin/Kanamycin and capreomycin (Pandey et 
al., 2003).  
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1.3 Respiratory System and Lung Anatomy  
The respiratory system consists of the conducting airway and respiratory 
regions (Figure 1.1). The conducting airway essentially consists of nasal cavity, 
nasopharynx, bronchi and bronchioles. Airways distal to the bronchioles 
constitute the respiratory region, which include the respiratory bronchioles, the 
alveolar ducts and the alveolar sacs. The latter structures (the alveoli), which 
are the important parts in this study, are composed almost exclusively of a 
nonciliated epithelial membrane. The alveolar walls contain a dense network of 
capillaries and connective tissue fibers (Suarez and Hickey, 2000). 
 
 
Figure1.1: Front view of cartilages of larynx, trachea, and bronchial tree (Gray,  
2001)  
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The lungs have in fact been demonstrated an efficient port of entry to the 
bloodstream due to: (i) the tremendous surface area of the alveoli (100 m2), 
immediately accessible to drug; (ii) a relatively low metabolic activity locally, as 
well as a lack of first-pass hepatic metabolism; and (iii) the elevated blood flow 
(5 l/min) which rapidly distributes molecules throughout the body (Fehrenbach, 
2001).  
  
The lungs have two separate circulations. The bronchial circulation, which 
involves small systemic arteries from the aorta supplies oxygen for the relatively 
high metabolic needs for lungs. The pulmonary circulation, which serves 
respiratory function, begins in the pulmonary artery; bring venous blood from 
the right atrium. The pulmonary arteries subdivide extensively and finally 
terminate in a dense capillary network around the alveoli. Venous blood returns 
to the left atrium via veins, which coalesce and eventually form the pulmonary 
venous system. The venous blood from the bronchial circulation returns to the 
system circulation via the azygous and pulmonary veins (Gray, 2001). 
 
1.4 Pulmonary Drug Delivery Systems  
Growing attention has been given to the potential of a pulmonary route as an 
non-invasive administration for systemic delivery of therapeutic agents due to 
the fact that the lungs could provide a large absorptive surface area (up to 100 
m2) with extremely thin (0.1 μm – 0.2 μm) absorptive mucosal membrane and 
good blood supply. Controlled release polymeric systems are approaches that 
help for improving the duration and effectiveness of inhaled drugs (Fu et al., 
2002).  
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Targeting delivery of drugs to the diseased lesions is one of the most important 
aspects of drug delivery systems. The systems should have novel properties 
such as increase efficiency of drug delivery, improve release profiles and drug 
targeting to the diseased site. Among the different dosage forms reported, 
nanoparticles and microparticles sized polymeric systems occupy unique 
position in drug delivery technology (Majeti and Kumar, 2000). 
 
The advantages of sustained drug delivery to the respiratory tract are 
numerous, and include extended duration of action, reduction in drug use, 
improved management of therapy, improved compliance, reduction in side 
effects and together with potential cost savings that exist for sustained release 
therapy (Cook et al., 2005). 
 
Malo et al. (1989) showed that four times daily treatment of asthma  with a 
corticosteroid resulted in less nocturnal cough attacks and relapses when 
compared to a twice daily schedule, with no change in the side effect profile. 
However, excessive dosing frequency is a well-documented cause of non-
compliance in patients. In another study Mann et al. (1992) reported that, 
inhaler under-usage was greater with four times daily versus twice daily 
treatment (57.1% versus 20.2%). Even in twice daily dosing, just 40% of 
patients complied with the given protocol, despite extensive education at the 
study onset. An inhaled sustained release formulation, administered once daily, 
would therefore provide benefit to non-compliant patient groups owing to the 
convenience of reduced dosing frequency (Cook et al., 2005). 
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Deol and Khuller. (1997) encapsulated antitubercular drugs (ATD) in liposomes. 
Sustained release of such drugs in the lung would be particularly beneficial 
since they could be delivered to and retained at the targeted receptors for a 
prolonged period of time and thus minimize the biodistribution throughout the 
systemic circulation (Zeng et al., 1995). This strategy helps to improve patient 
compliance in terms of reducing the dosage frequency, and can contribute in 
minimizing the risk of emergence of drug-resistance   and potential toxicity 
(Makino et al., 2004). 
   
1.5 Advantage of Pulmonary Delivery 
The pulmonary delivery route has attracted much attention, as well as nasal, 
rectal, injections and oral routes, to improve the quality of life of patients, 
because no dose repeated are required. Further, this route is desirable for 
delivering drugs because of the following advantages over other routes.  
(1) The surface area of a lung is extremely large (approximately 100 m2) and 
the mucosal permeation of drug substances is comparatively easy, because the 
vascular system is well developed and the wall of the alveolus is extremely thin 
(Yamamoto et al., 2005). 
(2) The activity of drug-metabolizing enzymes with intracellular or extracellular 
is relatively low, it avoids hepatic first-pass metabolism (Suarez and Hickey, 
2000).  
(3) A very rapid onset of action with very small dose. An oral dose of 
bronchodilator may take 2–3 h to be fully effective while an inhaled dose usually 
takes a minimum of 15–30 min (Zeng et al., 1995). 
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(4) Reduces exposure of drug to the systemic circulation and potentially 
minimizes adverse effects and lower dosage regimens may provide 
considerable cost saving especially with expensive therapeutic agents (Joshi 
and Misra, 2001). 
 
1.6 Pulmonary Delivery Devices  
Local delivery of medication to the lung is highly desirable, especially in patients 
with specific pulmonary diseases like cystic fibrosis, asthma, chronic pulmonary 
infections, or lung cancer. Aerosols are an effective method to deliver 
therapeutic agents to the respiratory tract. Metered dose inhalers (MDIs), dry 
powder inhalers (DPIs) or nebulizers are commonly used for this purpose 
(Finlay, 2001).  
 
There are numerous commercially available devices, and their design is an 
important factor governing aerosol size and fluid output. Although pressurised 
metered dose inhalers are the most commonly used inhalation drug delivery 
system, other delivery systems, such as dry powder inhalers and nebulizers, 
are widely used as propellant-free alternatives to MDIs (McCallion et al., 
1996a). Gupta and Hickey, (1991) reported that nebulizer inhalers compared to 
MDIs or DPIs, generate smaller particles, which are better penetration to the 
distal region of the lungs and, thus, are more suitable for systemic delivery. 
 
1.6.1 Metered Dose Inhalers (MDIs) 
The metered dose inhalers (MDIs) were the first apparatus, which is both 
reliable and practical (Timsina et al., 1994). The fundamental components of 
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MDIs are an actuator, a metering valve, and a pressurized container that holds 
the micronized drug suspension or solution, propellant, and surfactant. The high 
vapor pressure propellant supplies the energy for dispersion in these delivery 
systems (Suarez and Hickey, 2000). Chlorofluorocarbon (CFC) as a propellant 
for MDIs has been widely used for pulmonary drug delivery devices (Yamamoto 
et al., 1999). 
 
Chlorofluorocarbons based metered-dose therapeutic aerosols are in the 
process of being reformulated with more environmentally friendly propellants, 
such as hydrofluoroalkanes (HFAs). CFCs were reported to destroy ozone layer 
in the stratosphere and allow excessive ultraviolet radiation to reach the earth's 
atmosphere (Tashkin, 1999). HFAs were investigated as possible substitutes for 
CFCs because they shared similar desirable characteristics but non-ozone 
depleting. Despite the similarities with the CFCs, many additional difficulties 
were observed. HFAs were demonstrated to have toxic effects, modified the 
solubilities of drug and incompatibility with MDI components such as valves and 
container walls (Crowder et al., 2001).  
 
The main disadvantages of MDI, especially in young children and elderly who 
have difficulty to administer the drug alone since it require patient’s hand and 
breathe coordination. Another disadvantage is release the aerosol at high 
velocity. This ballistic effect causes deposition of approximately 65% of the 
medication in the upper respiratory tract (mouth, oropharynx and larynx). It 
became also known that only a small fraction (10-20%) of the emitted dose 
reaches the lower airways. The remainder deposits in the extrathoracic and 
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upper airways, are swallowed and subsequently absorbed in the gastrointestinal 
tract. The low temperature of the CFCs or HFAs discharged from a pMDI 
frequently also causes children to abruptly stop inhaling. All the disadvantages 
lead to a suboptimal delivery of drugs to the airways and thereby reduced 
therapeutic efficacy (Biddiscombe et al., 1993). 
 
1.6.2 Dry Powder Inhalers 
Dry powder inhalers (DPIs) can be divided into two classes: passive and active.  
1. Passive devices depend on the inhalation ability of patient’s to provide the 
energy needed for dispersion. 
2. Active powder-dispersion devices, similar to propellant-driven metered-dose 
inhalers, which use an external energy source to help the patient to accomplish 
some part of the aerosol dispersion (Crowder, 2004). 
 
DPIs are the most recent developed devices in respiratory therapy. The majority 
of these devices are breath-activated inhalers that rely on the patient's 
inspiratory flow to deaggregate and deliver the drug for inhalation, thereby 
eliminating the requirement of inhalation coordination inherent in pMDI use. 
However, with DPIs there is the need to generate at least moderate inspiratory 
flow in order to accomplish effective drug delivery. The drug in a DPI is in the 
form of a finely milled powder in large aggregates, either alone or in 
combination with some carrier substance (Byron et al., 1990). 
 
Most of the particles are initially too large to be carried into the lower airways, 
but the turbulent air stream created in the inhaler during inhalation causes the 
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aggregates to break up into primary particles sufficiently small to be carried into 
the lower airways. Therefore, the deposition pattern of the particles depends on 
the inspiratory flow generated by the patient. A very low inspiratory flow is likely 
to move the dose from the inhaler into the patient’s mouth, with very low 
deposition in the pulmonary air-ways. Shear, turbulence, and mechanical 
intervention may be used to aid in the dispersion of aerosols from dry powders 
(Suarez and Hickey, 2000). 
  
Dry powder generation is often hindered by aggregation of the small particles 
(Brown, 1987), which is in turn exacerbated by the hygroscopic nature of the 
drug and its electrostatic charge. The reduction of powder hygroscopic and 
electrostatic charge may enhance the future prospects of aerosol powder 
formulation (Ferron, 1977). 
 
1.6.3 Nebulizers  
Nebulizers use ultrasound or compressed gas to produce aerosol droplets in 
the respirable size range from liquids, usually aqueous solutions of drugs. They 
are widely used therapeutically to deliver corticosteroids, antiallergics, 
anticholinergics, antibiotics, mucolytics and other agents to the respiratory tract 
(British National Formulary, 1994). Further, the nebulizers are adaptable to very 
fine suspensions as well as aqueous solution (Yamamoto et al., 1999).  
 
Nebulizers have the advantage over MDIs and DPIs that the drug may be 
inhaled during normal breathing through a mouth-piece or facemask. Thus, they 
can be employed to deliver aerosolized drug to patients, such as children, the 
 12
elderly and patients with arthritis, who experience difficulties using other 
devices. Nebulizers can also deliver relatively large volumes of drug solutions 
and suspensions. They are frequently used for drugs that can not be 
conveniently formulated into an MDI or DPI or where the therapeutic dose is too 
large for delivery with the alternative systems (McCallion et al., 1996a). 
 
1.7 Preparation Techniques for Pulmonary Drug Delivery System  
Different drug carriers/delivery systems have been used for controlled drug 
delivery. In the last two decades, synthetic biodegradable polymers have been 
increasingly used as carrier to deliver drugs, because they are free from most of 
the problems associated with the natural polymers. Poly (amides), poly (amino 
acids), poly (alkyl-α-cyano acrylates), poly (esters), poly (orthoesters), poly 
(urethanes), poly (acrylamides) and ligands of carbonyl-
methoxypolyethyleneglycol (mPEG) and distearoylphosphatidylethanolamine 
(DSPE) have been used to prepare various drug-loaded devices to improve 
therapy. Amongst them, the thermoplastic aliphatic poly (esters) such as PLA, 
PGA, especially PLGA and niosomes (Non-ionic surfactant vesicles), as well as 
mPEG and DSPE based polymeric micelles have generated so much interest 
due to their excellent biocompatibility and biodegradability. However, recent 
approaches to improve patient compliance have involved instituting intermittent 
drug delivery regimens with the use of polymers by cleaving conventional 
antitubercular drugs to various types of carrier systems (Dutt and Khuller, 2001; 
Zhang et al., 2003). 
 
 13
1.7.1 Microspheres  
Microspheres are defined as homogenous monolithic spherical colloidal 
particles made of single or multiple type of polymers, typically with a particle 
size in the range of 1-200 µm, ideally <125 µm (Jain, 2000). Microspheres in 
strict sense are monolithic. However, the terms microcapsules and 
microspheres are often used synonymously. In addition, some related terms are 
used as well, for example, “micro beads” and “beads”. The term sphere and 
spherical particles are also used for a large size and rigid morphology (Majeti 
and Kumar, 2000). Microspheres have been used widely as drug carriers for 
controlled drug release (Hincal and Calis, 1999). Polymers, which have been 
extensively investigated for drug carriers, are (lactic acid) (PLA), poly (glycolic 
acid) (PGA) poly (lactic-co-glycolic acid) (PLGA). These polymers have 
excellent biocompatibility, mechanical strength, ease of fabrication, prolonged in 
vivo degradation kinetics, and changeable biodegradability properties (Pandey 
et al., 2003 and Zheng et al., 2004). The polymers have been fabricated into a 
variety of devices, such as microspheres, micelles, liposomes, nanospheres, 
film, implants, and pellets. Furthermore, their application in humans has been 
approved by food and drug administration (FDA). However, the disadvantages 
of this types of polymeric system particularly that of PLGA are low entrapment 
efficiency, burst release, instability of entrapped hydrophilic protein, and its 
incomplete release (Zheng et al., 2004). 
 
1.7.2 Microparticle Preparation 
The preparations of lung based drug delivery system have involved several 
processes. Hincal and Calis’s. (1999) reported that a wide range of 
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microencapsulation techniques. The selection of the technique depends on the 
nature of the polymer, the drug, the intended use and the duration of therapy 
(O'Donnell and McGinity, 1997). In preparing controlled release microspheres 
for efficient entrapment of the active substance, the choice of the method is 
importance. The microencapsulation methods for hydrophobic biodegradable 
polymers such as poly (lactide-co-glycolide) and poly (lactic acid) as matrix 
materials are: 
a) Emulsion-Solvent Evaporation and Solvent Extraction. 
b) Phase Separation (Coacervation). 
c) Interfacial Polymerisation  
d) Spray Drying. 
1.7.2 (a) Solvent Evaporation and Extraction Process 
The solvent evaporation method is widely used to produce microspheres. There 
are two systems from which to choose, oil in water (O/W) or water in oil (W/O) 
and (W/O/W). The choice of a particular method is usually determined by the 
solubility characteristics of the drug.  
i. Single Emulsion Process 
The method is ideal for water-insoluble drugs in which polymer are first 
dissolved in volatile organic solvent. The drug is then added to the polymer 
solution to produce a solution or dispersion of the drug particles. This polymer–
solvent–drug solution/dispersion is then emulsified (with appropriate stirring and 
temperature conditions) in a larger volume of water in presence of an emulsifier 
to yield an o/w emulsion. The emulsion is then subjected to solvent removal by 
either evaporation or extraction process to harden the oil droplets. The solid 
microspheres obtained are then washed and collected by filtration, sieving, or 
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centrifugation. The microspheres are then dried under appropriate conditions or 
lyophilised to give the final free flowing microsphere product (Bodmeier and 
McGinity, 1988; Torres et al., 1996; Jain, 2000).  
 
It should be noted that the solvent evaporation process in a way is similar to the 
extraction method, in the sense that the solvent must first diffuse out into the 
external aqueous dispersion medium before it could be removed from the 
system by evaporation (Arshady, 1991; Wu, 1995). 
 
In order to increase the encapsulation of the water-soluble drugs, an oil-in-oil 
(O/O) emulsification method was developed (Arshady, 1991 and Ramírez et al., 
1999). A water-miscible organic solvent is employed to solubilise the drug in 
which polymers are also soluble. This solution is then dispersed into oil such as 
light mineral oil in presence of an oil soluble surfactant like Span to yield the 
(O/O) emulsion. Microspheres are finally obtained by evaporation or extraction 
of the organic solvent from the dispersed oil droplets and the oil is washed off 
by solvents like n-hexane. This process is also sometimes referred as water-in-
oil (W/O) emulsification method (Jalil and Nixon, 1990a). 
  
ii. Double / Multiple Emulsion Process 
The process is best suited to encapsulate water-soluble drugs like peptides, 
proteins, and vaccines, unlike the o/w method which is ideal for water-insoluble 
drugs. The method is that a buffered or plain aqueous solution of the drug 
(sometimes containing a viscosity building and/or stabilizing protein like gelatin) 
is added to an organic phase consisting of polymer solution in organic solvent 
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with vigorous stirring to form the first w/o emulsion. This emulsion is added 
gently with stirring into large volume water containing an emulsifier like PVA to 
form the w/o/w emulsion. The emulsion is then subjected to solvent removal by 
either evaporation or extraction process. The solid microspheres obtained are 
then washed and collected by filtration, sieving, or centrifugation. The 
microspheres are then dried under appropriate conditions or lyophilized to give 
the final free flowing microsphere product (Jain, 2000). 
 
1.7.2 (b) Phase Separation (Coacervation) 
Coacervation is a process in which a homogeneous solution of macromolecules 
undergoes liquid-liquid phase separation, giving rise to a polymer rich dense 
phase. Coacervation has been classified into simple and complex processes 
depending on the number of participating macromolecules. In simple 
polyelectrolyte coacervation, addition of salt or alcohol normally promotes 
coacervation. In complex coacervation, two oppositely charged macromolecules 
(or a polyelectrolyte and an oppositely charged colloid) could undergo 
coacervation through associative interactions (Mohanty et al., 2004).  
 
The process consists of decreasing the solubility of the encapsulating polymer 
by addition of a third component to the polymer solution in an organic solution 
(Jalil and Nixon, 1990a). At a particular point, the process yields two liquid 
phases (phase separation): the polymer containing coacervate phase and the 
supernatant phase depleted in polymer. The drug which is dispersed/dissolved 
in the polymer solution is coated by the coacervate. Thus, the coacervation 
process includes the following three steps: (i) phase separation of the coating 
 17
polymer solution, (ii) adsorption of the coacervate around the drug particles, and 
(iii) solidification of the microspheres (Jain, 2000).  
 
The main disadvantages of this method are tendency to produce agglomerated 
particles, problem in mass production, requires large quantities of organic 
solvent, and difficult to remove residual solvents from the final microsphere 
product (Takada et al., 1995). 
 
1.7.2 (c) Interfacial Polymerization  
The method involves the condensation of two monomers at the interface of the 
organic and aqueous phases. Polyamide capsules are a good example of this 
system (Conti et al., 1992). The surface polymerization of the monomer 
surfactants is the advanced method of this technique for preparation of 
nanocapsules (Shapiro and Pykhteeva, 1998). 
 
1.7.2 (d) Spray Drying  
The spray drying technique appears to be attractive for the preparation of 
microparticles (Baras et al., 2000). It can be used for the microencapsulation of 
antigens. The technique consists of spraying an emulsion of polymer and drug 
through the nozzle of a spray dryer apparatus; the solvent evaporates very 
quickly, leaving solid microparticles (Pavanetto et al., 1992). The spray drying 
process involves the following four sequential stages: atomization of the product 
into a spray nozzle, spray air contact, drying of the sprayed droplets and 
collection of the solid product obtained. Due to the rapid evaporation of the 
solvent, the temperature of the droplets can be kept below the drying air 
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temperature, and for this reason spray-drying can be applied to heat-sensitive 
materials (Broadhead et al., 1992). 
 
The main advantages of the spray drying technique are applicable to both heat 
resistant and heat sensitive drugs, as well as water-soluble and water-insoluble 
drugs (Jain, 2000 and Mu et al., 2005). However, the method is associated with 
some drawback that included a significant loss of the product during spray-
drying, due to adhesion of the microparticles to the inside wall of the spray-drier 
apparatus, and agglomeration of the microparticles (Takada et al., 1995). 
Another limitation of spray drying is its unsuitability for substances sensitive to 
mechanical shear of atomization (Maa and Prestrelski, 2000 ) and amorphous 
materials which are hygroscopic, more cohesive and difficult to flow and 
disperse (Hak and Nora,  2003). 
 
1.7.3 Poly (Lactic-Co-Glycolic Acid) (PLGA)  
Poly(lactide-co-glycolide) PLGA is a highly biocompatible and biodegradable 
synthetic polymer, which is hydrolytically degraded into non-toxic oligomer and 
finally to lactic acid and glycolic acid (Ito and Makino, 2004). In general, poly 
lactic-co-glycolic acid (PLGA), poly lactic acid (PLA) and poly glycolic acid 
(PGA) are block copolymers of lactic and/or glycolic acid (Figure 1.2), with the 
monomers linked by ester bands. The final hydrolytic products are monomers 
glycolic and lactic acid. Both monomers enter the tricarboxylic acid cycle and 
can be eliminated from the body as carbon dioxide and water (Jain, 2000).   
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Chemically, lactic acid, which is a composite of PLGA, contains one more side 
methyl group and is more hydrophobic than glycolic acid. Therefore, the higher 
content of lactide, the more hydrophobic is the polymer, the lower water uptake 
and the slower the degradation rate. In addition, lactic acid in the polymer can 
either be in its optically active form (L) or as a racemate (D, L), which affects the 
crystallinity of the polymer. Besides hydrophobicity and crystallinity, MW and 
poyldispersity are also important molecular properties affecting polymer 
performance. Several other important bulk properties, like glass transition 
temperature, melting point, and solubility in organic solvents, water uptake rate 
and biodegradation rate are closely related to the molecular properties of PLGA 
polymers (Jain, 2000).  
 
 
Figure 1.2: Chemical structure of poly lactic-co-glycolic acid (PLGA) 
 
1.7.4 PLGA Microparticles for Lung Delivery 
Most previous studies of polymeric pulmonary drug delivery have utilized PLGA 
since it is readily available and has a long history of safety in humans (Fu et al., 
2002).  
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Masinde and Hickey. (1993) prepare poly (lactic acid) (PLA) microspheres with 
particle sizes between 1 and 11 µm by a solvent evaporation technique. The 
microspheres were suspended in a non-surfactant solution and subsequently 
atomized using a jet nebulizer. The particles generated were suitable for drug 
delivery to the lower airways, having a median diameter of 2 µm and geometric 
standard deviation of 2.4 µm. Zeng et al. (1995) studied tetrandrine antisilicotic 
alkaloid entrapped in albumin microspheres for delivery to the alveolar region. 
They observed tetrandrine metabolized in alveolar and incorporate into alveolar 
macrophages. 
 
Lai et al. (1993) reported prolonged protection against bronchoconstriction 
challenge in rats at least 12 h post-administration with PLGA/isoproterenol 
microspheres. Edwards et al. (1997) studied sustained release of insulin in rats 
with large porous particles fabricated from PLGA, and showed reduced 
macrophage uptake and immune response to the larger particles relative to 
non-porous controls. El-Baseir and Kellaway. (1998) studied the in vitro 
sustained release of beclomethasone diproprionate and nedocromil sodium 
entrapped in PLA microparticles for 8 and 6 days respectively. However, 
pulmonary administration of PLA microspheres to rabbits was associated with 
inflammation at sites adjacent to microparticle deposition, raised neutrophil 
count and incidence of haemorrhage (Armstrong et al., 1996). 
 
PLGA has many limitations as a carrier for drugs in the lungs. First, small 
amount of PLGA microspheres degrade over the period of weeks to months, but 
typically deliver drugs are released for a shorter period of time. Such a pattern 
 21
would lead to an unwanted build-up of polymer in the lungs upon repeat 
administration (Cook et al., 2005). Second, bulk degradation of PLGA 
microspheres creates an acidic core, which can damage pH sensitive drugs 
such as peptides and proteins. Surface eroding polymers, such as 
polyanhydrides, lessen the effect of acidic build-up by increased diffusion rates 
of soluble fragments away from the particle. Third, PLGA microspheres have 
hydrophobic surfaces, which result in sub-optimal particle flight into the deep 
lung (due to particle agglomeration by van der Waals forces) (Fu et al., 2002). 
Additionally, hydrophobic surfaces lead to rapid opsonization (protein 
adsorption), resulting in a rapid clearance by alveolar phagocytic cells (Cook et 
al., 2005). 
 
1.7.5 Polymeric Nanoparticles 
Nanoparticles are colloidal particles ranging in size from 10 to 1000 nm, and 
they are extensively employed for targeted drug delivery systems. 
Nanoparticles have several advantages over conventional drug carriers; small 
particle size, ease of administration, drug targeting to the specific body site, 
solubilization of hydrophobic drug, avoid the reticuloendothelical system (RES), 
and reduced side effects of anticancer drugs (Lee et al., 2003). 
 
Various drug delivery and drug targeting systems are currently developed or 
under development. Among drug carriers are soluble polymers, insoluble or 
biodegradable natural and synthetic polymers, microcapsules, nanocapsules, 
cells, cell ghosts, lipoproteins, liposomes, and micelles. Each of those carrier 
types offers its own advantages and has its own shortcomings, so the choice of 
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a certain carrier for each given case can be made only taking into account the 
whole bunch of relevant considerations (Torchilin, 2001). 
 
Among the various drug delivery systems considered for pulmonary application, 
biodegradable polymeric nanoparticles demonstrate several potential 
advantages. In comparison to liposomal formulations, polymeric nanoparticles 
may exhibit a greater stability in the face of extreme forces generated during the 
nebulization process, thus eliminating the possibility of drug leakage. A further 
advantage of nanoparticle formulations is the fact that particles with a diameter 
of <1 µm are more easily incorporated in the `respirable percentage' of 
aerosolized droplets (droplets exhibiting a mass median aerodynamic diameter 
(MMAD) of 1–5µ µm) (Lea et al., 2003). 
 
Drug targeting systems like liposomes (Codde et al., 1993) or prodrugs (O’Hare 
et al., 1989) have been limited with some disadvantages such as instability of 
carriers in the body fluid, rapid elimination by undesirable organs, difficulties in 
modifying macromolecular carriers, possibility of drug inactivation during 
chemical attachment, liberation rate of drug from the macromolecular-drug 
conjugates and biodegradation. Drug carrier systems of core-shell type 
nanoparticles reported by Peracchia et al. (1997), or polymeric micelles 
reported by Yokoyama et al. (1990), were attempted to solve the problems 
mentioned above. Nanoparticles based on core-shell structure or polymeric 
micelles have many advantages such as long circulation in the body, better 
drug solubility, drug stability and high drug encapsulation. However, polymeric 
micelles or core-shell type nanoparticles are found to have limited application 
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for specific drug targeting due to the drug may be freely diffused throughout the 
body (Jeong et al., 2005). 
 
Recently, block copolymers or polymeric conjugates were synthesized to make 
core-shell type nanoparticles and polymeric micelle. Polymeric micelles 
represent a separate class of micelles and are formed from polymers consisting 
of both hydrophilic and hydrophobic monomer units and they are more stable 
compared to micelles (Torchilin, 2001: Torchilin, 2002). Polymeric micelles have 
a hydrophobic core and a hydrophilic outer shell, in which hydrophobic 
segments form the inner-core of the structure, acts as a drug incorporation site, 
especially for hydrophobic drugs (Jeong et al., 1998). At present, polymeric 
micelles seem to be one of the most advantageous carriers for the delivery of 
water-insoluble drugs (Deol and Khuller, 1997; Jones and Leroux, 1999). 
 
Use of lipid moieties as hydrophobic blocks capping PEG chains can provide 
additional advantages for particle stability when compared with conventional 
amphiphilic polymeric micelles due to the existence of two fatty acid acyls which 
might contribute considerably to an increase in the hydrophobic interactions 
between the polymeric chains in the micelle’s core (Torchilin, 2002). 
 
Diacyllipid–PEG conjugates micelles have been introduced into the area of 
controlled drug delivery as polymeric surface modifiers for liposomes (Klibanov 
et al., 1990). Interestingly, diacyllipid–PEG molecule itself represents a 
characteristic amphiphilic polymer with a bulky hydrophilic (PEG) portion and 
short but extremely hydrophobic diacyllipid part. The diacyllipid–PEG 
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conjugates were found to form micelles of different sizes in an aqueous 
environment (Lasic et al., 1991). PEG–PE micelles can efficiently incorporate 
sparingly soluble drugs (Weissig et al., 1998a). It seems that the use of PEG-
diacyllipid conjugates, which represent micelle-forming amphiphilic polymers 
with larger hydrophilic blocks and more lipophilic hydrophobic blocks, might 
result in colloidal particles, which are more stable under physiologic conditions 
(Torchilin, 1999). 
 
1.7.6 PEG-PE Nanoparticles Preparation 
There are two principal methods for the preparation of polymeric micelles, the 
direct dissolution method and the dialysis method. In each particular case, the 
choice of the method is usually determined by the extent of the solubility of a 
micelle-forming in an aqueous medium. If the polymer is marginally soluble in 
water, the direct dissolution method is employed, whereas if the polymer is 
poorly soluble in water, the dialysis method is usually employed (Allen et al., 
1999). 
 
In direct dissolution method, a polymer is dissolved in an aqueous medium at 
normal or elevated temperature and at a concentration well above its CMC 
value. Usually, in direct dissolution method the copolymer produce micelles 
spontaneously in aqueous solution, but in some cases the copolymer and water 
are mixed at elevated temperatures to ensure micellization (Allen et al., 1999; 
Torchilin, 2001). This method is frequently applied for micelle preparation from 
block co-polymers possessing a certain degree of solubility in water (Torchilin, 
2001). 
